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Initial Metabolic Profiles Are Associated with 7-Day Survival among
Infants Born at 22-25 Weeks of Gestation
Scott P. Oltman, MS1, Elizabeth E. Rogers, MD2, Rebecca J. Baer, MPH3,4, James G. Anderson, MD2, Martina A. Steurer, MD5,
Matthew S. Pantell, MD2, J. Colin Partridge, MD2, Larry Rand, MD6, Kelli K. Ryckman, PhD7, and
Laura L. Jelliffe-Pawlowski, PhD1
Objective To evaluate the association between early metabolic profiles combined with infant characteristics and
survival past 7 days of age in infants born at 22-25 weeks of gestation.
Study design This nested case-control consisted of 465 singleton live births in California from 2005 to 2011 at
22-25 weeks of gestation. All infants had newborn metabolic screening data available. Data included linked birth
certificate and mother and infant hospital discharge records. Mortality was derived from linked death certificates
and death discharge information. Each death within 7 days was matched to 4 surviving controls by gestational age
and birth weight z score category, leaving 93 cases and 372 controls. The association between explanatory vari-
ables and 7-day survival was modeled via stepwise logistic regression. Infant characteristics, 42 metabolites, and
12 metabolite ratios were considered for model inclusion. Model performance was assessed via area under the
curve.
Results The final model included 1 characteristic and 11 metabolites. The model demonstrated a strong asso-
ciation between metabolic patterns and infant survival (area under the curve [AUC] 0.885, 95% CI 0.851-0.920).
Furthermore, a model with just the selected metabolites performed better (AUC 0.879, 95% CI 0.841-0.916) than
a model with multiple clinical characteristics (AUC 0.685, 95% CI 0.627-0.742).
Conclusions Use of metabolomics significantly strengthens the association with 7-day survival in infants born
extremely premature. Physicians may be able to use metabolic profiles at birth to refine mortality risks and inform
postnatal counseling for infants born at <26 weeks of gestation. (J Pediatr 2018;198:194-200).
R ecent improvements in neonatal resuscitation and intensive care have led to an increase in survival among infants bornat 22-25 weeks of gestation.1-3 These neonates suffer high rates of mortality and morbidity, especially at lower gesta-tional ages and birth weights.4-9 This makes decisions about resuscitation and use of active interventions difficult for
clinicians and families.2,10-13 Compounding the magnitude of clinical decisions regarding infants born extremely preterm is the
fact that up to 83% of deaths in infants born at 22-24 weeks of gestation occur in the first week of life.5
Given the uncertainty surrounding clinical management of periviable newborns, the American Academy of Pediatrics rec-
ommends that decisions regarding care should be individualized and family centered, taking into account conditions and risk
factors known to affect outcomes.14 There are several models to predict survival in this patient population, with the most widely
used model being the National Institute of Child Health & Human Development Neonatal Research Network (NRN) Ex-
tremely Preterm Birth Outcome calculator, by Tyson et al.15 However, all of these predictive models rely exclusively on clinical
characteristics of the infant.15-17
The use of unique sources of data and novel possible predictors may improve
survival prediction for infants born at <26 weeks of gestation. One such oppor-
tunity is the use of metabolic data measured as part of newborn screening (NBS)
for rare inborn errors of metabolism.18 Our group and others have shown that
infants born at term and preterm are metabolically distinct and that metabolic
profiles can be used for accurate gestational dating.19-23 Furthermore, metabo-
lites measured as part of routine NBS have been implicated in neonatal compli-
cations, including respiratory distress syndrome, patent ductus arteriosus, and
necrotizing enterocolitis.24,25
AUC Area under the curve
IVH Intraventricular hemorrhage
NBS Newborn screening
NRN Neonatal Research Network
ROC Receiver operating curve
TPN Total parenteral nutrition
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The objective of this study was to assess the relationship
between survival to 7 days of age and metabolic markers in
concert with common infant characteristics. We hypoth-
esized that the incorporation of metabolites would strengthen
the association with survival beyond the capacity of infant char-
acteristics alone.
Methods
This was a nested, case-control study within a retrospective
cohort of data collected by the California Office of Statewide
Health Planning and Development on births from 2005 to 2011
in California. This database contains information from hos-
pital discharge, birth certificate, and death records from birth
to 1 year of age. This database was combined with results from
NBS using date of birth, hospital of birth, birth weight, and
birth time. In California, the Newborn Screening Program (ad-
ministered by the California Department of Public Health)
screens all newborn infants for rare inborn metabolic dis-
eases by measuring markers in a heel-stick blood spot taken
between 12 hours and 8 days after birth. The program has been
described extensively elsewhere.26,27
There were 2 664 595 infants in the source cohort after
linkage with vital statistics. Infants were excluded if the birth
weight was >4 SDs from the mean for gestational age by sex
(to limit potential erroneous data),28 they were not single-
tons, they did not have complete NBS metabolic data (this in-
cludes infants who died after delivery but before their sample
could be analyzed), or if their NBS blood spot was not taken
within 72 hours of delivery (Figure 1; available at
www.jpeds.com). The population was then limited to infants
born at <26 weeks of gestation, leaving 1238 infants eligible
for analysis. From the final population, infants who died within
7 days were matched to 4 controls by gestational week of birth
and birth weight z-score category, which left a final sample of
93 cases and 372 controls (7 infants who died could not be
matched to a control).
The outcome of interest for this study was survival past 7
days of age. Henceforth, “survival” in our study will be defined
as alive after 7 days and “death” will be defined as deceased at
<7 days. Mortality data were obtained from death certificate
and death discharge information within the California Office
of Statewide Health Planning and Development dataset. Infant
and maternal characteristics used in analyses included birth
weight, gestational age, sex, delivery type, maternal educa-
tion, race/ethnicity, Medi-Cal status (California’s Medicaid),
use of total parenteral nutrition (TPN), birth weight small for
gestational age, and any intraventricular hemorrhage (IVH)
diagnosis (International Classification of Diseases, Ninth Revi-
sion, Clinical Modification codes 772.13, 772.14). Criteria for
choosing these specific variables included availability, occur-
rence before NBS, and previous evidence of an association with
early infant mortality. Administration of TPN was obtained
from the NBS data and was defined as receiving TPN before
the blood spot was taken. There were 42 metabolites entered
into the model consisting of 12 amino acids, 26 acylcarnitines,
free carnitine, 2 hormones, and 1 enzyme (Table I; available
at www.jpeds.com). In addition, 12 metabolic ratios were con-
sidered in the model.We used the same ratios created by NBS
to detect known inborn errors of metabolism. No additional
ratios were created.
Standardized mass spectrometry (tandem mass spectrom-
etry) was used to measure the amino acids, acylcarnitines, and
free carnitine. Thyroid-stimulating hormone and 17-
hydroxyprogesterone were measured by high-performance
liquid chromatography, and galactose-1-phosphate
uridyltransferase was measured with a fluorometric enzyme
assay.26
Statistical Analyses
All metabolites underwent a natural log transformation before
being used in analyses to minimize the skew and influence of
outlying observations. Birth weight was transformed into z
scores using standardized growth curves28 and then divided into
10 categories by increments of 0.5. Birth weight small for ges-
tational age was calculated for infants with birth weight <10th
percentile from standardized growth curves.28 Population char-
acteristics of interest and metabolites were summarized by the
use of means with SDs and frequencies with proportions for
continuous and categorical variables, respectively. Univariate
analyses used t tests and c2 tests for continuous and categori-
cal variables, respectively, to compare infants that survived and
those that did not.
Multivariable logistic regression was used to model the as-
sociation with survival. We used a stepwise regression proce-
dure that consecutively adds explanatory variables based on
minimizing P value from univariable analyses and then removes
any variables with newly recalculated P values that eclipse the
predetermined threshold. To maximize model performance,
all possible explanatory variables had the potential to enter the
model, and the criteria for remaining in the model was P < .10.
In addition, variables with a P ≥ .05 and < .10 were removed
if their inclusion raised the Akaike information criterion or
had no discernible positive effect on area under the curve (AUC)
from a receiver operating characteristic (ROC) curve. If both
base metabolites and their ratio were selected for inclusion in
the model, severe multicollinearity was assessed and the com-
ponents were evaluated independently with P values and con-
tribution to model AUC and Akaike information criterion. Age
at NBS collection and TPN were entered into the model build,
as both are well-known to influence values of NBS
metabolites,29-31 and if not selected, a model forcing them in
was compared with the original model. In addition, the model
was examined in subgroups stratified by TPN and by IVH to
compare predictive performance and metabolites of interest.
Performance of the final model was evaluated with AUC,
and variables were summarized via OR, 95% CI, and stan-
dardized parameter estimates. Cross-validation was applied to
assess the model fit, and the final model underwent condi-
tional logistic regression to test for bias due to matching. The
final model also was compared (using AUC, 95% CIs, and
model contrast tests) to models consisting of metabolites only
and clinical characteristics only (sex, IVH diagnosis, race/
ethnicity, maternal education, Medi-Cal status, and cesarean
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delivery). ROC-derived probability cut points were used to cal-
culate sensitivity and specificity, and odds of survival above
particular cut points were compared with that of the referent
cut point (<0.3) to generate ORs with 95% CIs.
All analyses were performed with SAS 9.3 (SAS institute,
Cary, North Carolina). Methods and protocols for the study
were approved by the Committee for the Protection of Human
Subjects within the Health and Human Services Agency of the
State of California and the institutional review board of the
University of California, San Francisco.
Results
The matched study sample included 93 infants who died and
372 survivors from a retrospective source population of 1238
infants born in California at 22-25 weeks of gestation from
2005 to 2011 with completed NBS. Within the source popu-
lation, 100 (8.1%) infants died at <7 days, and 305 (24.6%)
died within the first year with an average age of survival of
35.0 days. Each infant who died at <7 days was matched to 4
infants surviving >7 days of the same gestational age week
and approximate birth weight. In the matched sample, vari-
ables that differed significantly between infants that survived
and those that did not were TPN administration, IVH diag-
nosis, and age at NBS collection (Table II). In univariable
analysis of the metabolites, 3 enzymes and hormones, 3 amino
acids, 14 acylcarnitines, and 9 metabolic ratios differed sig-
nificantly between infants who survived and those who did
not (Table I).
The model most strongly associated with survival was ad-
justed for age at collection and contained 12 variables: IVH
diagnosis, alanine, ornithine, C-3, C-3DC, C-5OH,C-6, C-10:1,
C-12:1, C-14:1, C-16, and C-16:1 and had an area under the
ROC curve (AUC) of 0.885 (95% CI 0.851-0.920). Of all the
variables in the model, the 2 amino acids alanine and
ornithine were most robustly linked to survival with
standardized estimates of –0.60 and 0.52, respectively
(Table III).
The model maintained strong performance after cross-
validation (AUC 0.857, 95% CI 0.817-0.896). The full model
also performed better when compared with a metabolites-
only model (AUC 0.879, 95% CI 0.841-0.916, P = .278) or a
clinical characteristics-basedmodel (AUC 0.685, 95%CI=0.627-
0.742, P < .001; Figure 2). After conditional logistic regres-
sion was applied to the full model, there was minimal evidence
of bias due to matching (results not shown). The model re-
mained robust when adjusted or stratified by TPN and when
stratified by IVH. In fact, the model exhibited stronger per-
formance in infants without TPN administered before NBS
(AUC 0.935 vs 0.867) and in infants without IVH (AUC 0.918
vs 0.869; Table IV; available at www.jpeds.com).
Association with survival was evaluated with the use of prob-
ability cut points generated from the ROC curve. Of the 245
infants with a probability score ≥0.9, 240 (98.0%) survived.
These 240 infants also accounted for 64.5% of all infants who
ended up surviving, and they were 360 times more likely
(OR 360.0, 95% CI 91.6-1414.6) to survive when compared
with infants with a probability score <0.3. Alternatively, no
infants with probability scores <0.1 survived. This cut point
successfully discriminated the mortality of 15 (16.13%) infants
without misclassifying a survivor (Table V). When classifica-
tion was expanded to the full population, the positive predic-
tive value at a probability score of 0.9 was 99.2%, and the
Table II. Maternal demographics and infant characteristics in the matched sample and population sample
Demographics
Matched All
Survived past 7 days Did not survive 7 days P value Survived past 7 days Did not survive 7 days P value
n = 372 n = 93 n = 1138 n = 100
Gestational age, wk 23.9 (0.8) 23.9 (0.8) 1.00 24.3 (0.8) 23.9 (0.8) <.001
Birth weight, g 668 (111.4) 673.7 (117.9) .662 722.2 (149.2) 662.9 (124.7) <.001
Age at collection, h 37.5 (16.6) 30.2 (14.3) <.001 36.5 (16.3) 30.2 (14.3) <.001
Female 186 (50.0) 39 (41.9) .164 538 (47.3) 42 (42.0) .311
TPN 284 (76.3) 61 (65.6) .034 873 (76.7) 66 (66.0) .016
Small for GA 10 (2.7) 2 (2.2) .770 57 (5.0) 6 (6.0) .665
Cesarean delivery 202 (54.3) 64 (68.8) .011 684 (60.1) 70 (70.0) .052
Medi-Cal 197 (53.0) 52 (55.9) .609 626 (50.0) 57 (57.0) .701
IVH 175 (47.0) 66 (71.0) <.001 498 (43.8) 68 (68.0) <.001
Race .140 .093
White 57 (15.3) 14 (15.1) 163 (14.3) 16 (16.0)
Black 40 (10.8) 3 (3.2) 121 (10.6) 3 (3.0)
Hispanic 207 (55.6) 55 (59.1) 631 (55.4) 59 (59.0)
Asian 42 (11.3) 10 (10.8) 134 (11.8) 10 (10.0)
Other 26 (7.0) 11 (11.8) 89 (7.8) 12 (12.0)
Maternal education .879 .891
<12 y 128 (34.4) 31 (33.3) 394 (34.6) 33 (33.0)
12 y 89 (23.9) 26 (28.0) 281 (24.7) 28 (28.0)
>12 y 133 (35.8) 31 (33.3) 411 (36.1) 34 (34.0)
Unknown 22 (5.9) 5 (5.4) 52 (4.6) 5 (5.0)
GA, gestational age.
Continuous variables described using mean and SD and categorical variables using frequencies and proportions. T tests and c2 tests for continuous and categorical variables respectively were
used to compare cases and controls.
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negative predictive value at a probability score of 0.1 was 75.0%
(Table V).
Discussion
Using metabolic markers that are collected as a part of routine
NBS, we were able to successfully build an algorithm that
reliably classified infants who survived past 7 days of age when
born at 22-25 weeks of gestation. The final model consisted
of IVH diagnosis and 11 metabolites (9 acylcarnitines and 2
amino acids).
Past predictive models have exclusively used maternal and
infant characteristics to predict survival.15-17 Although the ma-
jority of infant mortality in neonates born extremely preterm
occurs within the first 24 hours after birth, another signifi-
Table III. Multivariable logistic regression model to predict survival past 7 days
Predictors
Survived past 7 days
(n = 372)*
Did not survive 7 days
(n = 93)*
Parameter
estimate OR (95% CI)
Model
P value
Standardized
estimate
IVH 175 (47.0) 66 (71.0) −0.92 0.40 (0.21-0.75) .005 −0.25
Age at collection 37.52 (16.6) 30.20 (14.3) 0.02 1.02 (1.00-1.05) .049 0.21
Alanine 5.36 (0.41) 5.59 (0.68) −2.26 0.11 (.05-0.24) <.001 −0.60
C-3 0.90 (0.4) 0.63 (0.5) 0.90 2.47 (1.08-5.62) .032 0.22
C-3DC −2.40 (0.50) −2.43 (0.48) −0.82 0.44 (0.22-0.88) .020 −0.22
C-5OH −1.52 (0.43) −1.77 (0.57) 0.91 2.49 (1.27-4.90) .008 0.24
C-6 −2.97 (0.8) 2.81 (0.8) −0.45 0.64 (0.41-1.00) .048 −0.20
C-10:1 −2.96 (0.96) −3.27 (1.07) 0.54 1.72 (1.20-2.45) .003 0.29
C-12:1 −3.54 (0.9) −3.45 (0.9) −0.40 0.67 (0.45-1.01) .055 −0.19
C-14:1 −2.35 (0.54) −2.23 (0.66) −1.32 0.27 (0.14-0.52) <.001 −0.41
C-16 0.13 (0.38) −0.15 (0.39) 1.59 4.92 (1.86-130) .001 0.35
C-16:1 −2.06 (0.5) −2.25 (0.6) 0.71 2.03 (1.05-3.94) .036 0.22
Ornithine 4.65 (0.5) 4.36 (0.6) 1.82 6.14 (2.82-13.41) <.001 0.52
All metabolites are natural log transformed.
*Frequency (%) and mean (SD) for categorical and continuous predictors, respectively.
Figure 2. Receiver operating curves for three different models of survival. aCombined model (AUC 0.885, 95% CI 0.851-
0.920) adjusted for age at collection consists of IVH diagnosis, alanine, C-3, C-3DC, C-5OH, C-6, C-10:1, C12:1, C14:1, C-16,
C-16:1, and ornithine. bCharacteristics only model (AUC 0.685, 95% CI 0.627-0.742) consists of sex, IVH diagnosis, race/
ethnicity, maternal education, Medi-Cal status, and caesarean delivery. cMetabolites-only model (AUC 0.879, 95% CI 0.841-
0.916) limited to metabolites from the final combined model adjusted for age at collection.
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cant portion occurs within the first week of life, and accurate
prediction is crucial for clinicians to appropriately counsel fami-
lies through difficult decisions about on-going aggressive
interventions.5,32,33 Currently, the most widely used predic-
tive model is the NRN’sWeb-based outcomes calculator, which
uses birth weight, gestational age, sex, exposure to antenatal
corticosteroids, and singleton or multiple gestation (AUC 0.751,
95% CI 0.735-0.767).15 When comparing our model combin-
ing characteristics and metabolites to the model used for the
NRN calculator, our model substantially improved perfor-
mance. Furthermore, the metabolites alone markedly outper-
formed both the model used for the NRN calculator and our
clinical characteristics-onlymodel. Themodel used for the NRN
calculator, however, performed better than our characteristics-
only model. This is likely due to the fact that our model was
matched on 2 of the NRN calculator’s strongest variables (birth
weight and gestational age) and the inclusion of antenatal cor-
ticosteroid exposure and singleton vs multiple gestation in the
NRN calculator model. These results demonstrate that meta-
bolic profiles may be of superior utility in the prognosis of sur-
vival for infants born extremely preterm, and with the addition
of antenatal corticosteroid and gestation information, perfor-
mance may be further improved. Moreover, metabolic pro-
files may point to etiologic pathways that could inform care.
Newborn metabolomics have been shown to be related to
gestational age and birth weight, especially in infants born
preterm.20,21,23 To minimize the influence of these factors on
our model and to delineate independent metabolic profiles,
we matched cases and controls by gestational age and birth
weight z-score category. The success of the model under these
circumstances suggests that infants who are less likely to survive
have metabolic dysfunction that is unrelated to growth re-
striction or gestational age. This is further supported by the
low proportion of birth weights that were small for gesta-
tional age among infants who did not survive in our sample.
Because growth in utero relies on maternal glucose via pla-
cental transfer, the metabolic dysfunction in the infants who
did not survive was possibly related to the inability to main-
tain independent glucose homeostasis.34,35 Indeed, the 2 biggest
correlates of survival in our model were relatively low con-
centrations of alanine and high concentrations of ornithine.
Alanine is an important substrate in gluconeogenesis, and a
build-up of alanine is emblematic of low enzymatic activity
downstream.36 Ornithine, in contrast, plays a crucial role in
cell proliferation, microvascularization, and kidney develop-
ment, and the relatively high concentrations in neonates who
survive are likely indicative of a properly functioning orni-
thine cycle.37 Further disruptions in glucose homeostasis can
lead to abnormal concentrations of acylcarnitines, which are
essential to beta-oxidation in the fetal liver.34,38 These path-
ways of metabolic function may help explain how our model
can be associated with survival using metabolic markers in-
dependently from birth weight and gestational age.
IVH was the only clinical diagnosis included as a variable
in our model due to the fact that approximately 50% of cases
occur on the first day of life and 90% by day 3,39,40 which is
the same time frame required for NBS sampling.Unsurprisingly,
lack of an IVH diagnosis was associated with survival. This is
supported in the literature, as mortality rates for IVH range
from 4% for grade I to 40% for grade IV.41 Moreover, severe
IVH in a neonate may lead to the withdrawal of intensive care
measures.42 Given the complex relationship between IVH and
survival, we examined the model in subsets of the sample as
stratified by IVH. Regardless of IVH status, our model per-
formed well, but unsurprisingly, the metabolites of impor-
tance varied between stratums. Specifically, the acylcarnitines
C-5OH and C-14:1 were particularly important to survival in
infants with IVH, suggesting they may be indicative of IVH
severity and justifying further investigation.
Both age at NBS collection and administration of TPN were
entered into our model because they are known to affect the
concentrations of metabolites.29-31 Age at NBS remained in our
model after selection, and a delay in collection was associ-
ated with increased survival. The most likely explanation for
this is the positive correlation between probability of sur-
vival and infant age. TPN, however, failed to tolerate the se-
lection process of the model build. As a result, we assessed the
performance of our model after forcing in TPN and after strati-
fying the infant population based on TPN administration. The
model displayed robust performance in all 3 scenarios, sug-
gesting that TPN did not significantly alter the association with
survival. It is important to note, however, that particular
Table V. Performance of the final survival model at various probability cut points
Survived past
7 days (n)
Did not survive
7 days (n) OR (95% CI)
Sensitivity
(95% CI)
Specificity
(95% CI) PPV* (95% CI) NPV* (95% CI)
Samples 372 93
≥0.9 240 5 360.0† (91.6-1414.6) 64.5 (59.4-69.4) 94.6 (87.9-98.2) 99.2 (98.2-99.7) 18.5 (15.3-22.2)
≥0.8 296 19 116.8† (37.3-366.0) 79.6 (75.1-83.6) 79.6 (70.0-87.2) 97.8 (96.6-98.7) 24.8 (20.2-29.9)
≥0.7 321 31 77.6† (25.7-234.8) 86.3 (82.4-89.6) 66.7 (56.1-76.1) 96.8 (95.6-97.8) 29.7 (23.9-36.1)
≥0.6 342 41 62.6† (21.0-186.5) 91.9 (88.7-94.5) 55.9 (45.2-66.2) 96.0 (94.7-97.1) 35.6 (28.2-43.6)
≥0.5 354 52 51.1† (17.3-150.8) 95.2 (92.5-97.1) 44.1 (33.8-54.8) 95.0 (93.5-96.2) 36.7 (28.1-46.0)
≥0.4 364 59 46.3† (15.7-136.1) 97.9 (95.8-99.1) 36.6 (26.8-47.2) 94.4 (93.1-95.8) 41.9 (31.3-53.0)
≥0.3 368 63 43.8† (14.9-128.6) 98.9 (97.3-99.7) 32.3 (22.9-42.8) 94.2 (92.7-95.5) 48.5 (36.0-61.1)
<0.3 4 30 Reference
<0.1 0 15 — 100.0 (99.0-100.0) 16.1 (9.3-25.2) 93.0 (91.4-94.4 75.0 (50.9-91.3)
NPV, negative predictive value; PPV, positive predictive value.
*PPV and NPV calculated using the entire cohort.
†P value <.001.
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acylcarnitines had varying levels of importance between TPN
stratums, warranting additional examination of the role TPN
exposure plays within newborn metabolomics.
Our study had several strengths and limitations. Perhaps the
most potent strength of our study is that our matched sample
was derived from a population-based dataset that supports the
potential generalizability of the model. Although we did not
use separate training and validation datasets because of the very
small number of babies born at very early gestations, we did
use cross-validation as a means for ensuring our results were
not due to overfitting. Our source data set was retrospective
in nature, limiting us to the use of predetermined explana-
tory variables and outcome data. This was especially impor-
tant as related to the NBS data. Infants who died before NBS
could be obtained were not included in the model build. Al-
though this limited our ability to examine survival no sooner
than at 7 days and produced a smaller sample, we do not think
it biased the results. We suspect that infants who died before
NBS was completed would likely have had compromised meta-
bolic functions to an even greater extent, and this may have
improved the performance of our model. Nevertheless, future
studies should assess metabolic function in infants who die
within hours of birth. Given the retrospective data, we may
not have been able to control for all factors affecting meta-
bolic concentrations. Blood transfusions, for example, could
have affected the values of metabolites, although, only in rare
scenarios in which a transfusion occurs before NBS. An ad-
ditional limitation of our data was the lack of information about
antenatal corticosteroid exposure, which has been shown to
be a powerful predictor of survival,15,43,44 and investigating the
value of adding it to our model will be essential.
Our model should be validated in other clinical and
population-based samples, preferably in a prospective setting.
Validation of the model is essential to determine whether these
metabolic patterns have predictive capacity.Moreover, the popu-
lation of California that was used in this study is especially
diverse, and the majority of infants in our study were of His-
panic ethnicity. Testing the model in other populations will
help expand the generalizability of our results. In addition, our
study focused on the association with survival at just one time
point (7 days), and it may be that metabolic profiles are linked
to survival at time-points beyond 7 days.Our study also focused
on a single measurement of metabolic markers. To truly
examine the probability of survival and elucidate the meta-
bolic pathways that differentiate infants, measuring markers
at multiple time points may be especially important. Further-
more, although NBS results currently require time for pro-
cessing and interpretation that preclude them from being
actively included in real-time decision-making, developing point
of care testing is essential. Finally, given the value of meta-
bolic correlates shown here, additional studies using them in
the prediction of morbidities associated with preterm birth are
warranted.
This study examined the link between routinely available
metabolic markers and survival in extremely preterm new-
borns. We successfully built a model showing strong associa-
tions and demonstrated that infants who survived beyond 7
days were metabolically different from those infants who died
in the first 7 days. Physicians potentially could use metabolic
profiles measured shortly after birth to refine mortality risks
and inform postnatal counseling for extremely premature
infants. ■
Data from the California Prenatal and Newborn Screening Programs
were obtained through the California Biobank Program (Screening In-
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for the results or conclusions drawn by the authors of this publication.
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Figure 1. Flow chart of infants born in California between 2005
and 2011 eligible for analysis.
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Table I. T tests comparing mean concentrations of individual metabolites between infants who survived ≥7 days and
those who did not
Metabolites
Survived ≥7 days
Mean (SD)
Did not survive >7 days
Mean (SD) P value
Enzymes and hormones
17 Hydroxyprogesterone 5.08 (0.69) 5.24 (0.62) .047
Thyroid-stimulating hormone –0.41 (1.08) −0.06 (0.79) .004
Galactose-1-phosphate uridyltransferase 5.23 (0.30) 5.04 (0.35) <.001
Amino acids
5-Oxoproline 3.29 (0.67) 3.37 (0.57) .292
Alanine 5.36 (0.41) 5.59 (0.68) <.001
Arginine 2.89 (0.81) 2.88 (1.02) .898
Citrulline 2.86 (0.45) 2.91 (0.53) .391
Glycine 6.15 (0.34) 6.17 (0.42) .619
Leucine/isoleucine 5.06 (0.48) 4.98 (0.72) .228
Methionine 3.53 (0.88) 3.51 (1.07) .854
Ornithine 4.65 (0.47) 4.36 (0.62) <.001
Phenylalanine 4.32 (0.31) 4.33 (0.49) .905
Proline 5.14 (0.54) 5.30 (0.77) .020
Tyrosine 4.84 (0.81) 5.01 (0.86) .064
Valine 5.04 (0.46) 4.95 (0.68) .151
Amino acid ratios
Arginine/ornithine ratio −1.76 (0.68) −1.49 (0.72) .001
Citrulline/arginine ratio −0.03 (0.75) 0.03 (0.79) .431
Leucine/alanine ratio –0.30 (0.39) −0.60 (0.46) <.001
Ornithine/citrulline ratio 1.79 (0.47) 1.45 (0.47) <.001
Phenylalanine/tyrosine ratio −0.51 (0.74) −0.68 (0.60) .041
Tyrosine/ornithine 0.18 (0.81) 0.65 (0.71) <.001
Valine/phenylalanine ratio 0.71 (0.33) 0.62 (0.36) .021
Carnitines
Free carnitine 3.85 (0.43) 3.70 (0.47) .003
C-2 3.16 (0.34) 3.03 (0.34) .001
C-3 0.90 (0.43) 0.63 (0.47) <.001
C-3DC −2.40 (0.50) −2.43 (0.48) .710
C-4 −0.61 (0.41) −0.72 (0.49) .040
C-5 −0.78 (0.44) −0.94 (0.51) .002
C-5:1 −3.37 (0.74) −3.41 (0.88) .604
C-5DC −2.07 (0.44) −2.02 (0.39) .350
C-5OH −1.52 (0.43) −1.77 (0.57) <.001
C-6 −2.97 (0.81) −2.81 (0.77) .080
C-8 −2.60 (0.81) −2.69 (0.87) .367
C-8:1 −2.57 (0.90) −2.79 (0.97) .037
C-10 −3.13 (0.79) −3.14 (0.80) .969
C-10:1 −2.96 (0.96) −3.27 (1.07) .007
C-12 −2.78 (0.80) −2.65 (0.69) .146
C-12:1 −3.54 (0.86) −3.45 (0.89) .405
C-14 −1.99 (0.42) −2.08 (0.43) .048
C-14:1 −2.35 (0.54) −2.23 (0.66) .071
C-14OH −4.07 (0.89) −3.99 (0.78) .452
C-16 0.13 (0.38) −0.15 (0.39) <.001
C-16:1 −2.06 (0.55) −2.25 (0.62) .004
C-16OH −3.60 (0.87) −3.65 (0.92) .637
C-18 −0.45 (0.45) −0.69 (0.39) <.001
C-18:1 −0.18 (0.37) −0.42 (0.41) <.001
C-18:1OH −3.97 (0.82) −3.92 (0.78) .598
C-18:2 −1.22 (0.77) −1.56 (0.84) <.001
C-18OH −4.43 (0.79) −4.34 (0.87) .357
Carnitine ratios
C-3/C-2 ratio −2.26 (0.34) −2.41 (0.36) <.001
C-5/C-3 ratio −1.68 (0.48) −1.57 (0.52) .054
C-5DC/C-3DC ratio 0.34 (0.34) 0.40 (0.37) .090
C16OH/C16 ratio −3.73 (0.87) −3.51 (1.01) .037
FC/(C16 + C18:1) ratio 3.16 (0.44) 3.27 (0.47) .024
All metabolites are natural log transformed.
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Table IV. Multivariable model performance with TPN forced in, stratified by TPN, and stratified by IVH
Predictors
Forced TPN (AUC 0.887) Without TPN (AUC 0.935) With TPN (AUC 0.867)
Survived
past 7 days
(n = 372)*
Did not
survive 7 days
(n = 93)* OR (95% CI)
Model
P value
Survived past
7 days (n = 88)*
Did not
survive 7 days
(n = 32)* OR (95% CI)
Model
P value
Survived
past 7 days
(n = 284)*
Did not
survive 7 days
(n = 61)* OR (95% CI)
Model
P value
IVH 175 (47.0) 66 (71.0) 0.40 (0.21-0.76) .005 40 (45.5) 24 (75.0) 0.2 (.04-0.94) .0415 135 (47.5) 42 (68.9) 0.52 (0.25-1.08) .079
TPN 284 (76.3) 61 (65.6) 0.84 (0.41-1.73) .634 – – – – – – – –
Age at collection 37.52 (16.6) 30.20 (14.3) 1.03 (1.00-1.05) .049 29.69 (14.5) 26.03 (11.7) 1.02 (0.94-1.09) .678 39.95 (16.4) 32.39 (15) 1.02 (1.00-1.05) .082
Alanine 5.36 (0.41) 5.59 (0.7) 0.10 (.05-0.24) <.001 5.26 (0.4) 5.6 (0.8) .06 (.01-0.33) .001 5.39 (0.4) 5.58 (0.6) 0.12 (0.04-0.34) <.001
C-3 0.90 (0.4) 0.63 (0.5) 2.46 (1.08-5.61) .033 0.98 (0.4) 0.49 (0.4) 12.48 (0.98-159.4) .052 0.88 (0.4) 0.7 (0.5) 1.56 (0.61-3.97) .355
C-3DC –2.40 (0.50) –2.43 (0.5) 0.45 (0.23-0.91) .026 –2.53 (0.5) –2.63 (0.5) 0.35 (.06-2.17) .261 –2.37 (0.5) –2.32 (0.5) 0.43 (0.19-0.96) .04
C-5OH –1.52 (0.43) –1.77 (0.6) 2.48 (1.25-4.94) .009 –1.53 (0.5) –1.75 (0.5) 1.88 (0.28-12.64) .515 –1.51 (0.4) –1.79 (0.6) 3.29 (1.19-9.05) .021
C-6 –2.97 (0.8) 2.81 (0.8) 0.63 (0.41-0.99) .045 –2.92 (0.8) –2.83 (0.8) 0.52 (0.18-1.53) .238 –2.99 (0.8) –2.8 (0.8) 0.63 (0.37-1.06) .083
C-10:1 –2.96 (0.96) –3.27 (1.1) 1.72 (1.21-2.46) .003 –3.24 (1.0) –3.58 (1.0) 1.64 (0.77-3.49) .196 –2.88 (0.9) –3.11 (1.1) 1.74 (1.13-2.68) .012
C-12:1 –3.54 (0.9) –3.45 (0.9) 0.67 (0.45-1.01) .055 –3.53 (0.9) –3.58 (1.0) 0.51 (0.21-1.2) .122 –3.54 (0.9) –3.39 (0.8) 0.85 (0.51-1.39) .507
C-14:1 –2.35 (0.54) –2.23 (0.7) 0.27 (0.14-0.52) <.001 –2.33 (0.6) –2.25 (0.7) 0.16 (0.04-0.69) .013 –2.35 (0.5) –2.21 (0.6) 0.26 (0.11-0.6) .002
C-16 0.13 (0.38) –0.15 (0.4) 4.88 (1.84-12.9) .001 0.2 (0.4) –0.23 (0.4) 12.58 (1.21-130.56) .034 0.12 (0.4) –0.11 (0.3) 4.73 (1.58-14.14) .005
C-16:1 –2.06 (0.5) –2.25 (0.6) 2.03 (1.05-3.94) .036 –1.98 (0.5) –2.3 (0.6) 1.08 (0.17-6.7) .934 –2.09 (0.6) –2.23 (0.6) 2.26 (1.14-4.5) .02
Ornithine 4.65 (0.5) 4.36 (0.6) 6.42 (2.88-14.30) <.001 4.39 (0.4) 4.06 (0.5) 19.98 (1.73-231.21) .017 4.73 (0.5) 4.51 (0.6) 5.15 (2.01-13.17) <.001
Without IVH (AUC 0.918) With IVH (AUC 0.869)
Predictors
Survived past 7 days
(N = 197)*
Did not survive 7 days
(N = 27)* OR (95% CI)
Model
P value
Survived past 7 days
(N = 175)*
Did not survive 7 days
(N = 66)* OR (95% CI)
Model
P value
IVH — — — — — — — —
TPN — — — — — — — —
Age at collection 38.41 (16.8) 29.63 (16.2) 1.03 (0.99-1.07) .143 36.53 (16.3) 30.44 (13.5) 1.01 (0.98-1.05) .474
Alanine 5.35 (0.4) 5.51 (0.7) .04 (.01-0.26) <.001 5.37 (0.4) 5.62 (0.7) .09 (.03-0.26) <.001
C-3 0.92 (0.4) 0.73 (0.5) 2.72 (0.55-13.41) .219 0.88 (0.4) 0.59 (0.5) 1.98 (0.69-5.71) .208
C-3DC –2.43 (0.5) –2.30 (0.5) 0.18 (.05-0.65) .009 –2.38 (0.5) –2.48 (0.4) 0.64 (0.27-1.54) .322
C-5OH –1.52 (0.5) –1.71 (0.8) 1.53 (0.56-4.15) .406 –1.51 (0.4) –1.80 (0.4) 8.73 (2.09-36.47) .003
C-6 –2.88 (0.7) –2.67 (0.6) 0.38 (0.1-1.45) .156 –3.08 (0.9) –2.87 (0.8) 0.73 (0.44-1.2) .213
C-10:1 –3.00 (1.1) –3.54 (1.1) 2.05 (1.15-3.66) .015 –2.92 (0.8) –3.16 (1) 1.65 (0.95-2.85) .075
C-12:1 –3.49 (0.8) –3.24 (0.5) 0.33 (0.13-0.85) .022 –3.59 (0.9) –3.54 (1) 0.87 (0.53-1.43) .592
C-14:1 –2.31 (0.5) –2.21 (0.5) 0.46 (0.14-1.57) .216 –2.39 (0.6) –2.23 (0.7) 0.21 (0.08-0.52) <.001
C-16 0.20 (0.4) –0.09 (0.4) 6.98 (1.28-38.09) .025 0.06 (0.4) –0.18 (0.4) 4.18 (1.08-16.21) .038
C-16:1 –2.04 (0.6) –2.26 (0.8) 3.9 (1.39-10.91) .01 –2.09 (0.5) –2.25 (0.5) 1.46 (0.59-3.6) .417
Ornithine 4.67 (0.5) 4.34 (0.6) 13.79 (2.78-68.46) .001 4.64 (0.5) 4.37 (0.6) 6.49 (2.39-17.59) <.001
All metabolites are natural log transformed.
*Frequency (%) and mean (SD) for categorical and continuous predictors, respectively.
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